ONE YEAR OF DUODENAL-JEJUNAL BYPASS LINER THERAPY (ENDOBARRIER®) LEADS TO SIGNIFICANT CHANGES IN LIVER BIOCHEMISTRY ASSOCIATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE - Ruban, A; Glaysher, M; Miras, A; Prechtl, CG; Goldstone, AP; Johnson, NA; Aldhwayan, M; Chhina, N; Al-Najim, W; Ashrafian, H; Patel, M; Byrne, J; et al. (MOSBY-ELSEVIER, 2020)